NCIt definition : A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable
fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused
to one that is directed against the CD3 antigen found on T-lymphocytes, with potential
immunostimulating and antineoplastic activities. Upon administration, emerfetamab
binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen
found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing
tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor
cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent
hematopoietic stem cells and overexpressed on a variety of cancer cell types, including
acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation
and progression.;
UNII : HOG226RYH1;
CAS number : 2250261-27-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2250261-27-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)